Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GLS | O94925 | 6/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | CFD | P00746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17764428 | 0.94 | SUCNR1 (0.44) | HDAC1SUCNR1DYRK1AKDM4EGLS | |
| SCHEMBL16410431 | 0.91 | HDAC1 (0.37) | HDAC1SUCNR1DYRK1AMAPTTDP1 | |
| SCHEMBL16410308 | 0.91 | LMNA (0.41) | HDAC1SUCNR1DYRK1AKDM4EMAPT | |
| SCHEMBL16410323 | 0.91 | DYRK1A (0.37) | HDAC1DYRK1AMAPTTDP1GLS | |
| SCHEMBL16410346 | 0.89 | HDAC1 (0.36) | HDAC1SUCNR1DYRK1AKDM4EMAPT | |
| SCHEMBL16410326 | 0.89 | HDAC1 (0.36) | HDAC1SUCNR1DYRK1AMAPTTDP1 | |
| SCHEMBL17764353 | 0.85 | SUCNR1 (0.41) | HDAC1SUCNR1DYRK1AKDM4EGLS | |
| SCHEMBL17764316 | 0.85 | SUCNR1 (0.41) | HDAC1SUCNR1DYRK1AGLSLMNA | |
| SCHEMBL17764271 | 0.85 | HDAC1 (0.37) | HDAC1SUCNR1DYRK1AKDM4EMAPT | |
| SCHEMBL17764474 | 0.83 | SUCNR1 (0.40) | HDAC1SUCNR1DYRK1AGLSLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| WO-2015009977-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | CFD, CFH, CFB | HDAC1 3377/4885SUCNR1 4670/4885DYRK1A 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.